What changed
IASO Biotechnology has completed the acquisition of Singapore-based immune cell engineering company MediSix Therapeutics, adding a proprietary T-cell fratricide-prevention platform and a Phase I clinical asset targeting CD7-positive T-cell malignancies to its existing CAR-T portfolio. The deal extends the China-based company's cell therapy footprint beyond its approved anti-BCMA product into hematologic indications where conventional CAR-T approaches have been technically constrained, with financial terms not disclosed and MediSix set to operate as an integrated unit within IASO Bio.
The technology behind the deal
MediSix's core asset is the Protein Expression Blocker (PEBL) platform, founded on research by Professor Dario Campana of the National University of Singapore's Yong Loo Lin School of Medicine, described as a pioneer of the 4-1BB co-stimulatory domain used widely in current CAR-T constructs. The PEBL technology blocks surface expression of target proteins — such as CD7 — on engineered T cells via endoplasmic reticulum and Golgi retention, preventing fratricide without gene editing. This approach is intended to enable CAR-T cells to target antigens shared between malignant and healthy T cells, a technical barrier that has limited cell therapy development in T-cell malignancies.
The clinical program
The lead program, IASO107 (formerly PCART7), is an autologous anti-CD7 CAR-T therapy currently in Phase I clinical evaluation at international research hospitals, with early efficacy and safety signals disclosed by the company. The asset is positioned as the first clinical candidate from the PEBL platform to enter human studies, and its progress will determine how quickly the acquired technology translates into registrational-stage development.
Strategic context and infrastructure
The acquisition gives IASO Bio a Singapore-based research and clinical operation at a moment when the company is building its international presence rather than relying solely on outbound licensing of existing assets. IASO Bio received approval from Singapore's Health Sciences Authority for its BCMA-targeted equecabtagene autoleucel (Fucaso) in June 2026 and has separately licensed equecabtagene autoleucel to Instituto Butantan for development in Brazil. The MediSix transaction adds a Singapore-domiciled team and a novel platform to that infrastructure.
What remains uncertain
Financial terms, the precise structure of the consideration, and any geographic restrictions on development rights were not disclosed in the announcement. The early efficacy and safety signals for IASO107 have so far only been disclosed by the company itself, with no independent peer-reviewed data yet available, and the timeline to any later-phase trials or regulatory filings has not been stated.
Follow-up signals
The next verifiable milestone is further clinical read-out from the Phase I evaluation of IASO107 at international research hospitals, alongside any disclosure of milestone payments or development obligations tied to the acquisition. Investors and partners will also be watching for integration milestones as MediSix becomes an integrated unit within IASO Bio, and for any regulatory submissions tied to equecabtagene autoleucel in Brazil under the Instituto Butantan license.
Share this article
